Marly

Researchers are studying migraine with aura to evaluate the effect of amiloride, a drug that blocks Acid-Sensing Ion Channels involved in migraine mechanisms. This proof-of-concept Phase 2 study compares amiloride to placebo to see if it can help prevent migraine aura attacks. The study is conducted at three headache centers in France and aims to explore a new treatment approach for people with this condition. Participants will receive either amiloride or placebo for 12 weeks, followed by a 4-week break, then switch to the other treatment for another 12 weeks. This randomized crossover study allows each participant to try both treatments in sequence. The double-blind design means neither participants nor researchers know which treatment is given at each stage. During the study, researchers will track the number of migraine aura attacks over 12 weeks as the main measure. They will also record migraine headache days and the impact of migraines on daily functioning. Participants will be monitored for safety and treatment adherence throughout the study. The total treatment period for each participant is about 28 weeks, including both treatment phases and the wash-out period.